Brokerages Set United Therapeutics Corporation (NASDAQ:UTHR) Target Price at $509.50

United Therapeutics Corporation (NASDAQ:UTHR) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $509.50.

A number of research firms recently commented on UTHR. UBS Group increased their price objective on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th.

United Therapeutics Stock Performance

UTHR stock opened at $478.93 on Tuesday. The stock’s 50 day moving average price is $486.76 and its 200 day moving average price is $425.24. The firm has a market cap of $20.62 billion, a P/E ratio of 18.15, a PEG ratio of 2.57 and a beta of 0.85. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $519.99.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $470.95, for a total transaction of $10,596,375.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $483.25, for a total value of $4,010,975.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,774,418.25. The trade was a 18.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 542,214 shares of company stock valued at $260,031,533 over the last quarter. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics during the 4th quarter valued at $26,000. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth $29,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Finally, Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.